ID: ALA609728
Chembl Id: CHEMBL609728
Cas Number: 848640-34-6
PubChem CID: 5276854
Max Phase: Preclinical
Molecular Formula: C10H15N3O2
Molecular Weight: 209.25
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Cc1ccc(NCCCN)c([N+](=O)[O-])c1
Standard InChI: InChI=1S/C10H15N3O2/c1-8-3-4-9(12-6-2-5-11)10(7-8)13(14)15/h3-4,7,12H,2,5-6,11H2,1H3
Standard InChI Key: FKZUPMCBVURANR-UHFFFAOYSA-N
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| Molecular Weight: 209.25 | Molecular Weight (Monoisotopic): 209.1164 | AlogP: 1.66 | #Rotatable Bonds: 5 |
| Polar Surface Area: 81.19 | Molecular Species: BASE | HBA: 4 | HBD: 2 |
| #RO5 Violations: ┄ | HBA (Lipinski): 5 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): ┄ |
| CX Acidic pKa: ┄ | CX Basic pKa: 9.82 | CX LogP: 1.81 | CX LogD: -0.51 |
| Aromatic Rings: 1 | Heavy Atoms: 15 | QED Weighted: 0.44 | Np Likeness Score: -1.60 |
| 1. Pan C, Mezei M, Mujtaba S, Muller M, Zeng L, Li J, Wang Z, Zhou MM.. (2007) Structure-guided optimization of small molecules inhibiting human immunodeficiency virus 1 Tat association with the human coactivator p300/CREB binding protein-associated factor., 50 (10): [PMID:17444627] [10.1021/jm070014g] |
| 2. Hewings DS, Rooney TP, Jennings LE, Hay DA, Schofield CJ, Brennan PE, Knapp S, Conway SJ.. (2012) Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions., 55 (22): [PMID:22924434] [10.1021/jm300915b] |
| 3. Furdas SD, Carlino L, Sippl W, Jung M. (2012) Inhibition of bromodomain-mediated proteinprotein interactions as a novel therapeutic strategy, 3 (2): [10.1039/C1MD00201E] |
| 4. Bamborough P, Chung C. (2015) Fragments in bromodomain drug discovery, 6 (9): [10.1039/C5MD00209E] |
| 5. Humphreys PG, Bamborough P, Chung CW, Craggs PD, Gordon L, Grandi P, Hayhow TG, Hussain J, Jones KL, Lindon M, Michon AM, Renaux JF, Suckling CJ, Tough DF, Prinjha RK.. (2017) Discovery of a Potent, Cell Penetrant, and Selective p300/CBP-Associated Factor (PCAF)/General Control Nonderepressible 5 (GCN5) Bromodomain Chemical Probe., 60 (2): [PMID:28002667] [10.1021/acs.jmedchem.6b01566] |
| 6. Huang L, Li H, Li L, Niu L, Seupel R, Wu C, Cheng W, Chen C, Ding B, Brennan PE, Yang S.. (2019) Discovery of Pyrrolo[3,2- d]pyrimidin-4-one Derivatives as a New Class of Potent and Cell-Active Inhibitors of P300/CBP-Associated Factor Bromodomain., 62 (9): [PMID:30998845] [10.1021/acs.jmedchem.9b00096] |
| 7. Vaidergorn MM, da Silva Emery F, Ganesan A.. (2021) From Hit Seeking to Magic Bullets: The Successful Union of Epigenetic and Fragment Based Drug Discovery (EPIDD + FBDD)., 64 (19.0): [PMID:34591474] [10.1021/acs.jmedchem.1c00787] |
Source(1):
